CTSO — Stock Film
STOCK FILMSCENE 1/11CTSO · $0.36
Stock Expert AI presents
CTSO
Cytosorbents Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Cytosorbents Corporation. A quick introduction.

On the stock market since 2006, it operates in the world of health and science. It has 129 employees. Now — the numbers.

on the stock market since 2006
129 employees
$22.6M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.2.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
99%Grant income
Grant income 99%Other sales 1%
99% of all revenue comes from a single line: Grant income.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $29.1M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
39 buy11 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
42
weak

Clearly below the class average.

FINANCIAL STRENGTH
18
very weak

Clearly below the class average.

VALUATION
28
very weak

Clearly below the class average.

GROWTH
53
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
17
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $37.1M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 39 buys and 11 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Running at a loss

A loss of $8.2M against $37.1M in annual sales.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.36. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, CTSO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: CTSO is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film